1. Frolkis, A.D., et al., Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology, 2013. 145(5): p. 996-1006.
2. Turner, D., et al., STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021. 160(5): p. 1570-1583.
3. Torres, J., et al., ECCO guidelines on therapeutics in Crohn's disease: Medical treatment. J Crohns Colitis, 2020. 14(1): p. 4-22.
4. Jeuring, S.F., et al., Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. Am J Gastroenterol, 2017. 112(2): p. 325-336.
5. Peyrin-Biroulet, L., et al., Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for Treat-to-Target. Am J Gastroenterol, 2015. 110(9): p. 1324-38.
6. Shinagawa, T., et al., Rate of reoperation decreased significantly after year 2002 in patients with Crohn's disease. Clin Gastroenterol Hepatol, 2020. 18(4): p. 898-907.e5.
7. Tsai, L., et al., Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: A meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol, 2020.
8. Froslie, K.F., et al., Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology, 2007. 133(2): p. 412-22.
9. Shah, S.C., et al., Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther, 2016. 43(3): p. 317-33.
10. Schnitzler, F., et al., Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis, 2009. 15(9): p. 1295-301.
11. von Roon, A.C., et al., Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol, 2007. 102(4): p. 803-13.
12. van Rheenen, P.F., E. Van de Vijver, and V. Fidler, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Bmj, 2010. 341: p. c3369.
13. Mosli, M.H., et al., C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am J Gastroenterol, 2015. 110(6): p. 802-19; quiz 820.
14. Colombel, J.-F., et al., Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet, 2017. 390(10114): p. 2779-2789.
15. Ng, S.C., et al., Incidence and phenotype of inflammatory bowel disease based on results from the Asia- pacific Crohn's and colitis epidemiology study. Gastroenterology, 2013. 145(1): p. 158-165.e2.
16. Shinzaki, S., et al., Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohns Colitis, 2017. 11(1): p. 84-91.
17. Yao, T., T. Matsui, and N. Hiwatashi, Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum, 2000. 43(10 Suppl): p. S85-93.
18. Gomollón, F., et al., 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis, 2017. 11(1): p. 3-25.
19. Best, W.R., et al., Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 1976. 70(3): p. 439-44.
20. Manceau, H., et al., Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med, 2017. 55(4): p. 474-483.
21. Fujimoto, M., et al., Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol, 2015. 67(8): p. 2056-60.
22. Ishii, A., New biomarker LRG for inflammatory bowel disease. J Anal Bio-Sci, 2021. 44(3): p. 55-63.
23. Daperno, M., et al., Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc, 2004. 60(4): p. 505-12.
24. Solem, C.A., et al., Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis, 2005. 11(8): p. 707-12.
25. Click, B., et al., Silent Crohn's disease: Asymptomatic patients with elevated C-reactive protein are at risk for subsequent hospitalization. Inflamm Bowel Dis, 2015. 21(10): p. 2254-61.
26. Oh, K., et al., Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One, 2017. 12(6): p. e0179266.
27. Stallmach, A., et al., Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther, 2016. 44(11-12): p. 1199-1212.
28. Dotan, I., et al., Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis, 2014. 20(12): p. 2247-59.
29. Fasanmade, A.A., et al., Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther, 2010. 48(5): p. 297- 308.
30. Florin, T.H., et al., Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol, 2006. 41(3): p. 306-11.
31. Laterza, L., et al., Multiparametric evaluation predicts different mid-term outcomes in Crohn's disease. Dig Dis, 2018. 36(3): p. 184-193.
32. de Dombal, F.T. and A. Softley, IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut, 1987. 28(4): p. 474-81.
33. Nakarai, A., et al., Slight increases in the disease activity index and platelet count imply the presence of active intestinal lesions in C-reactive protein-negative Crohn's disease patients. Intern Med, 2014. 53(17): p. 1905-11.
34. Sands, B.E., Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology, 2015. 149(5): p. 1275-1285.e2.
35. Heida, A., K.T. Park, and P.F. van Rheenen, Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: A systematic review and practical guide. Inflamm Bowel Dis, 2017. 23(6): p. 894-902.
36. Langhorst, J., et al., Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol, 2008. 103(1): p. 162-9.
37. Rokkas, T., P. Portincasa, and I.E. Koutroubakis, Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis, 2018. 27(3): p. 299-306.
38. Sollelis, E., et al., Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease. World J Gastroenterol, 2019. 25(19): p. 2354-2364.
39. Yasutomi, E., et al., Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep, 2021. 11(1): p. 11086.
40. Shinzaki, S., et al., Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol, 2021. 56(6): p. 560-569.
41. Kawamoto, A., et al., Serum leucine-rich α(2) glycoprotein: A novel biomarker for small bowel mucosal activity in Crohn's disease. Clin Gastroenterol Hepatol, 2021.